Regeneron sold $170 million worth of Praluent in the United States last year, and Sanofi sold over $200 million worth in the rest of the world.Ī Delaware judge threw out a jury verdict for Amgen in 2019 after finding patents related to Repatha invalid. Food and Drug Administration approved Praluent in 2015, a month before it approved Repatha. The drug, which lowers "bad" LDL cholesterol using monoclonal antibodies to block a protein that prevents its removal, can reduce the risk of heart attacks and strokes in people with heart disease.Īmgen sued Sanofi and Regeneron in 2014 after they sought regulatory approval for their rival drug Praluent. Thousand Oaks, California-based Amgen sold more than $1.1 billion worth of Repatha worldwide last year.
0 Comments
Leave a Reply. |